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wards. Main outcomes are pathogens and resistance identi-
fied in HAUTIs and urosepsis including its clinical sever-
ity. A statistical model that included demographic factors 
(study year, geographical location, hospital setting) was 
used for analysis.
Results Amongst urology practices, the prevalence of 
microbiologically proven HAUTI and urosepsis was 5.8 
and 1.5 %, respectively. Frequent pathogens in urosepsis 
were E. coli (43 %), Enterococcus spp. (11 %), P. aer-
uginosa (10 %) and Klebsiella spp. (10 %). Resistance to 
commonly prescribed antibiotics was high and rates ranged 
from 8 % (imipenem) to 62 % (aminopenicillin/β lacta-
mase inhibitors); 45 % of Enterobacteriaceae and 21 % of 
P. aeruginosa were multidrug-resistant. Resistance rates 
in urosepsis were higher than in other clinical diagnosis of 
HAUTI (Likelihood ratio <0.05).
Conclusions It is not appropriate to use the pathogen 
spectrum and resistance rates of other HAUTIs as repre-
sentative of urosepsis to decide on empirical treatment of 
Abstract 
Objective Primary objective was to identify the (1) rela-
tionship of clinical severity of urosepsis with the pathogen 
spectrum and resistance and (2) appropriateness of using 
the pathogen spectrum and resistance rates of health-care-
associated urinary tract infections (HAUTI) as representa-
tive of urosepsis. The secondary objective was to provide 
an overview of the pathogens and their resistance profile in 
patients with urosepsis.
Population and Methods A point prevalence study car-
ried out in 70 countries (2003–2013). Population studied 
included; 408 individuals with microbiologically proven 
urosepsis, 1606 individuals with microbiological proof 
of HAUTI and 27,542 individuals hospitalised in urology 
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urosepsis. Resistance rates in urosepsis are high, and pre-
cautions should be made to avoid further increase.
Keywords Urosepsis · Pathogens · Resistance · 
Prevalence
Introduction
Sepsis is known to have high mortality rates (severe sepsis: 
28 % and septic shock: 41 %) and urinary tract infections 
(UTI) are one of the leading causes (severe sepsis: 9 % and 
septic shock: 31 %) [1–4]. Rapid and appropriate manage-
ment of sepsis, including the administration of an initially 
adequate intravenous antibacterial, is essential for optimal 
outcomes [1]. However, compared to other causes of sepsis, 
inadequate coverage was identified as an outstanding prob-
lem in urosepsis [5]. Therefore, evidence about the patho-
gen spectrum and antibacterial resistance especially in uro-
sepsis needs to be well collected. Unfortunately, data on 
pathogen spectrum and resistance are usually derived from 
studies that investigated overall hospital acquired urinary 
tract infections (HAUTI), but not urosepsis [6]. Therefore, 
appropriateness of this approach needs questioning. Addi-
tionally, there is a lack of knowledge of pathogen spectrum 
and resistance in different clinical severity forms of sepsis 
that is associated with mortality outcomes [2, 3].
The primary aims of the present analysis were to iden-
tify (1) relationship of clinical severity of urosepsis with 
the pathogen spectrum and resistance and (2) appropriate-
ness of using the pathogen spectrum and resistance rates 
of HAUTIs as representative of urosepsis. In addition, a 
timely description of the pathogens and their resistance 
profile in patients with urosepsis at urology departments 
was aimed at.
Materials and methods
The global prevalence of infections in urology (GPIU) 
study
GPIU study is a web-based multinational, multicentre point 
prevalence study performed annually on select days of 
November annually since 2003 on November of each year 
to investigate infections in hospitalised urological patients 
only. Each centre was allowed to join the study in only a 
single day every year from several time points within 
November. Participating centres provided information on 
hospital and urology ward characteristics and practice. 
At 8 a.m. of the selected study day, all urological patients 
presently hospitalised in the department were screened for 
the presence of HAUTI. The investigators have to state for 
each reported patient whether the infection is a HAUTI or 
not. Clinical diagnosis, individual characteristics, interven-
tion characteristics, culture outcomes and antibiotic treat-
ment of patients with HAUTI were documented. Clini-
cal diagnosis criteria that also included criteria for sepsis 
severity were provided as part of the protocol to be used for 
clinical classification (eMethods). Standards used for urine 
cultures susceptibility assessment were noted (eTable-1). 
Data of the years 2003 and 2004 were combined in one 
group due to data file structure changes made in 2005 [7]. 
Study centres were categorised according to the geographi-
cal locations (Europe, Asia, South America and Africa) and 
hospital type (University, Teaching, District and others).
GPIU data from 2003 to 2013 were reviewed, and uro-
sepsis (sepsis emerging through a UTI) patients with 
microbiological proof of infection were identified. A sum-
mary of cases included in the current analysis is provided 
in eFigure-2.
Pathogens and susceptibility profile in urosepsis
Pathogens
All urine and blood cultures were analysed in the local 
laboratories according to their microbiological standards. 
Pathogen spectrum is listed in Table 1 and antimicrobial 
susceptibility of pathogens in Table 2. Pathogens with a 
frequency below 1 % were grouped as ‘others’.
Resistance profile
Resistance rates were determined for 10 antibiotics and 
eight antibiotic combinations (Table 2). These were reg-
istered as resistant, intermediate and sensitive. For anal-
ysis intermediate and resistant isolates were grouped 
together.
Frequently used antibiotics in urology were identified 
from previous publications of the GPIU [8]. Combinations 
of these that do not have a common resistance mechanism 
were analysed for resistance. These were: ceftazidime and 
piperacillin/tazobactam each combined with ciprofloxacin, 
gentamicin or TMP/SMX, and the combinations cipro-
floxacin and gentamicin or TMP/SMX. This was done by 
combining the resistance categories and obtaining a three-
tier grouping as: (1) resistant to both agents, (2) resistant to 
single agent and (3) sensitive to both agents.
MDR pathogens
Multidrug-resistant bacteria classification was carried out 
according to the ECDC and CDC definitions of multidrug 
(MDR), extensive drug (XDR) and pan-drug resistance 
(PDR) [9]. For this purpose, pathogens were classified as 
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Enterobacteriaceae, P. aeruginosa and others. Some antibi-
otics needed for a complete ECDC resistance classification 
(teicoplanin, telavancin, tigecycline, daptomycin, chloram-
phenicol, moxifloxacin and streptogramins) were absent in 
the GPIU.
Comparison of clinical severity of urosepsis
Data on severity of urosepsis were collected from 2007 
onwards using the following classification: simple urosep-
sis, severe urosepsis, and uroseptic shock [10–12]. Severe 
sepsis and septic shock were grouped together and com-
pared with simple urosepsis.
Appropriateness of using HAUTIs as representative 
of urosepsis
All patients within the GPIU study were stratified accord-
ing to the clinical diagnosis. These were: asymptomatic 
bacteriuria (ASB), male accessory gland infection (MAGI), 
cystitis, pyelonephritis and urosepsis. Comparisons were 
made except for ASB as it is not regarded as an infection 
[13].
Statistical analysis
Study data were imported from the web-based portal into 
SPSS v.20.0 (SPSS Inc., Chicago, IL, USA) for analysis.
Bacterial spectrum and resistance rates were the pri-
mary outcome. Categorical data were compared with the 
Chi-square test. A logistic regression model was generated 
to determine parameters that influence studied outcomes. 
Baseline parameters included in the model were: hospi-
tal type, geographical location and study year (e-figure 3). 
Urosepsis severity and type of non-urosepsis HAUTI 
(excluding ASB) were added in the baseline model sepa-
rately. Parameters that influence the outcomes significantly 
were identified with the Likelihood ratio test at a signifi-
cance level of 95 %. Identified parameter magnitude and 
direction of influence on outcomes are presented as odds 
ratios (OR) with confidence intervals (CI) at a 95 % level 
of significance.
Table 1  Pathogen spectrum in urosepsis, its subgroups (geographical location, sepsis severity) and other HAUTIs (MAGI, cystitis, pyelonephri-
tis)
a Severity of sepsis was included in the logistic regression model analysis that already included geographical region, study year and hospital 
type. Based on this model, severity of sepsis was found not to influence the pathogen spectrum (Likelihood ratio test [=0.342)
Geographical location was the only parameter to influence pathogen frequency (shown in previous steps)
b Sepsis severity was collected after 2007
Pathogen Geographical location Sepsis severitya,b Clinical diagnosis Overall 
urosepsis
Europe
n (%)
Asia
n (%)
Africa
n (%)
Americas
n (%)
Simple  
urosepsis
n (%)
Severe  
urosepsis and 
uroseptic shock
n (%)
MAGI
n (%)
Pyelone-
phritis
n (%)
Cystitis
n (%)
Gram negative
 E. coli 127 (41 %) 34 (52 %) 8 (38 %) 5 (50 %) 121 (46.9 %) 29 (37.2 %) 77 (37 %) 190 (45 %) 240 (43 %) 174 (43 %)
 Klebsiella spp. 25 (8 %) 8 (11 %) 6 (29 %) 3 (30 %) 24 (9.3 %) 9 (11.5 %) 17 (8 %) 54 (13 %) 73 (13 %) 42 (10 %)
 P. aeruginosa 39 (13 %) 3 (5 %) 0 0 24 (9.3 %) 11 (14. %1) 25 (12 %) 34 (8 %) 48 (9 %) 42 (10 %)
 Enterobacter spp. 19 (6 %) 2 (3 %) 0 2 (20 %) 14 (5.4 %) 6 (7.7 %) 13 (6 %) 20 (5 %) 42 (7 %) 23 (6 %)
 Proteus spp. 14 (4 %) 0 2 (10 %) 0 7 (2.7) 4 (5.1) 7 (3 %) 27 (6 %) 34 (6 %) 16 (4 %)
 Acinetobacter 
spp.
2 (1 %) 5 (8 %) 0 3 (1.2 %) 3 (3.8 %) 1 (1 %) 6 (1 %) 9 (2 %) 7 (2 %)
 Citrobacter spp. 3 (1 %) 1 (2 %) 0 0 2 (0.8 %) 0 2 (1 %) 7 (2 %) 8 (1 %) 4 (1 %)
Gram positive
 Enterococcus. 37 (12 %) 5 (8 %) 4 (19 %) 0 27 (10.5 %) 9 (11.5 %) 23 (11 %) 41 (10 %) 55 (10 %) 46 (11 %)
 S. aureus 12 (4 %) 3 (5 %) 0 0 12 (4.7 %) 2 (2.6 %) 7 (3 %) 7 (2 %) 18 (3 %) 15 (4 %)
CoNS 8 (3 %) 1 (2 %) 0 0 7 (2.7 %) 0 11 (5 %) 6 (1 %) 9 (2 %) 9 (2 %)
 Other gram (+) 
cocci
4 (1 %) 0 1 (5 %) 0 3 (1.2) 0 (0.0) 4 (2 %) 0 4 (1 %) 5 (1 %)
Other bacteria 13 (4 %) 0 0 0 9 (3.5 %) 3 (3.8 %) 18 (9 %) 21 (5 %) 17 (3 %) 13 (3 %)
Fungi 8 (3 %) 4 (6 %) 0 0 5 (1.9 %) 2 (2.6 %) 2 (1 %) 14 (3 %) 7 (1 %) 12 (3 %)
Total 311 66 21 10 258 78 207 427 564 408
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Results
Prevalence of urosepsis
Diagnosis of HAUTI was made in 2107 (7.7 %) cases 
amongst 27,542 patients screened. Microbiological proof of 
infection was available in 1606 (5.8 %) cases. In total, 408 
patients had microbiologically proven urosepsis (25.4 % of 
HAUTIs; 1.5 % of total study day population)(e-Figure 2).
Cases were registered from Europe (n:311–76 %), 
Asia (n:66–16.1 %), Africa (n:21–5.1 %) and USA (n:10–
2.4 %). Type of hospital cases were registered from uni-
versity (n:228–56 %), teaching (n:107–26 %), district 
(n:69–17 %) and others (n:4–1 %). Mean age of patients 
with urosepsis was 63 ± 17 years, and the female-to-
male ratio was 3:7. Mean Charlson comorbidity score was 
2.48 ± 2.61 [14]. An intervention prior to the episode of 
urosepsis was reported in 324 (79 %) cases (clean: n:77–
24 %, clean contaminated: n:99–31 %, clean contaminated 
with bowel segments opened: n:57–18 %, contaminated: 
n:28–9 %, infected: n:63–19 %, missing: n:2). A uri-
nary catheter at the time of diagnosis was present in 287 
(70 %) cases, and urinary tract obstruction was reported in 
234 (57 %) cases. Urolithiasis was reported in 20 % (n:76, 
missing n:21) of cases.
Simple sepsis was seen in 258 (77 %) and severe sepsis/
septic shock in 78 (23 %) patients. Remaining 72 patients 
were not classified for severity of sepsis.
Pathogens and susceptibility profile in urosepsis
Pathogens
Pathogen order from most frequent to least is as follows: 
E. coli > Enterococcus spp. > P. aeruginosa > Klebsiella 
spp. > Enterobacter spp. > Proteus spp. > S. aureus > Can-
dida spp. > CoNS > Acinetobacter spp. > Citrobacter spp. 
(Table 1).
The pathogen spectrum showed annual fluctuations, but 
this was not accompanied by an overall trend of change 
(Likelihood ratio p > 0.05) (e-Figure-4). Geographical 
location was the only parameter to influence pathogen 
spectrum (Likelihood ratio p = 0.001) (Table 1).
Resistance profile of pathogens
Overall resistance rates were lowest for imipenem (8 %), 
while for all other remaining antibiotics, resistance ranged 
from 36 to 62 % (Table 2). Geographical variation in 
the resistance rates of ampicillin/BLI (Likelihood ratio 
p = 0.05), gentamicine (Likelihood ratio p = 0.01) and 
piperacillin/tazobactam + gentamicin (Likelihood ratio 
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fluctuation in the resistance rates was not statistically sig-
nificant (Likelihood ratio p > 0.05) (e-Figure-4).
MDR pathogens
MDR rates for Enterobacteriaceae (n:259–63.4 %) was 
45 %, and for P. aeruginosa (n:42–10.3 %) it was 21 %. 
Remaining rare pathogen subgroups (n:107–26.2 %) were 
not classified for MDR due to insufficient numbers to carry 
out analysis. Further categorisation into XDR etc. was not 
performed due to missing full antibiotic susceptibility test-
ing against antibiotics.
Comparison of clinical severity of urosepsis
Bacterial spectrum did not differ according to sever-
ity (Likelihood ratio test p = 0.34) (Table 1). Resistance 
rates for single agents in simple and severe urosepsis 
ranged from 8 to 60 and 7 to 64 %, respectively (Table 2). 
Rates of resistance for ceftazidime and two of its combi-
nations tested (large confidence intervals) were signifi-
cantly higher in simple sepsis (multiple logistic regression 
analysis.
Appropriateness of using HAUTIs as representative 
of urosepsis
Clinical diagnosis of HAUTI with microbiological proof 
were as follows: pyelonephritis (n:427–27 %), cystitis 
(n:564–35 %) and MAGI (n:207–13 %). Pathogen distribu-
tion varied according to clinical diagnosis (Likelihood ratio 
test p = 0.012) (Table 1).
Highest resistance rates against all antibiotics and anti-
biotic combinations were observed in urosepsis compared 
with other HAUTIs (Table 2). These were statistically 
significant for ampicillin + BLI, levofloxacin, cefuro-
xime, cefotaxime, ceftazidime, ceftazidime + gentamicin, 
ceftazidime + ciprofloxacin and piperacillin/tazobac-
tam + ciprofloxacin (logistic regression model) (Table 2).
Discussion
Prevalence of urosepsis
Urosepsis prevalence in urology patients was 1.5 %, and a 
quarter of patients with HAUTI were diagnosed with uro-
sepsis. There are no directly comparable studies looking 
at urology patients in specific. Urosepsis rates in intensive 
care units (ICU) amongst patients with infections from 
a study conducted in Germany were 30.8 % (severe and 
shock) [15]. Another study reporting on nosocomial UTIs 
treated by non-urological departments identified the rate 
of severe urosepsis and uroseptic shock as 2 and 0.3 %, 
respectively [16].
Pathogens and susceptibility profile in urosepsis
Annual pathogen spectrum was similar throughout the 
11-year study time frame. Gram negatives contributed to 
approximately 75 %. This is different than reports of over-
all sepsis showing Gram positives (52 %) as the leading 
pathogen followed by Gram negatives (37 %) [2]. In the 
GPIU study pathogen spectrum differed with geographical 
region, previously shown in the SENTRY study also [17]. 
However, the published SENTRY results did not provide 
details on the clinical diagnosis of UTIs.
The presented antibiotic resistance rates are of great 
concern. The only antibiotic group with a resistance rate 
below 10 % were carbapenems, which is comparable to 
other HAUTIs we previously reported [18]. Remaining 
other antibiotic group resistance was above 36 %. Given 
the fact that for empiric treatment of severe infections 
resistance rates should not be higher than 10 %, we have 
limited options in urosepsis [11].
Fluctuations of annual resistance rates in urosepsis were 
not accompanied by a time trend of change within the study 
years. This finding seems counterintuitive as most studies 
report a concern of increase in resistance [6, 19]. However, 
resistance rates in our study are higher than the previous 
reports. For instance, a study from the UK with a cohort 
from urology patients including all HAUTIs reported 
a resistance rate below 25 % for E. coli to ciprofloxacin, 
which is almost half the rate we identified at baseline 
2003/4 [6]. Capture of a meaningful change in our cohort 
with already high rate of resistance would require substan-
tial changes. Therefore, the current results show that resist-
ance rates in urology practice of urosepsis are already high.
One strategy to mitigate high resistance rates for empiri-
cal treatment can be the use of combination treatment of 
different antibiotic classes, until susceptibility results allow 
test specific treatment. Overall resistance rates for combi-
nation of antibiotics ranged from 24 to 40 %. Combina-
tions showed resistance rates less than most single agents 
and not influenced from location or time. Resistance of 
single agents was published by ECDC in 2013 was similar 
to the GPIU while combination rates were markedly lower 
in ECDC [20]. However, the ECDC report is not directly 
comparable with the GPIU as it is not representative of uro-
logical patients. Further studies of combination agents in 
urosepsis are needed.
Recent reports of MDR pathogens are of significant con-
cern both for hospital and community acquired infections 
[21, 22]. However, lack of a universal clinical definition 
for MDR in these studies limits interpretations. In the cur-
rent analysis, we attempted to use the latest definition by 
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ECDC/CDC of MDR to provide coherent results [9]. The 
GPIU registry started prior this definition, and we lacked 
some of the antibiotics required in their definitions limit-
ing our ability of an accurate classification. Nevertheless, 
considering MDR pathogens are resistant to one or more 
antibiotics in two or more antibiotic categories [9], the 
scale of the problem becomes more apparent. The new 
MDR classification was easily identified in our data. Future 
study designs that include CDC/ECDC definitions of MDR 
would provide coherent comparison amongst different 
studies.
Resistance rates were lowest in Europe where a statis-
tically significant difference was observed with ceftazi-
dime, gentamicin and ampicillin + BLI. In our previously 
published analysis, the antibiotic consumption in regions 
seemed to overlap with the resistance rates identified in 
the current analysis [23]. As expected, geographical areas 
with higher consumption of antibiotics do also have higher 
resistance rates in urosepsis.
Comparison of clinical severity of urosepsis
Arguably due to higher rate of mortality [2, 3] and resource 
consumption [24–26], more attention has been paid to 
severe sepsis than to simple. Within the GPIU cohort, three 
quarter of urosepsis patients were simple cases that may 
shift to a more severe vignette if not managed appropri-
ately. In the current analysis, resistance was not associated 
with severity. The only exception for this was a statistically 
significant lower resistance rate in severe cases for ceftazi-
dime, ceftazidime + TMP/SMX and ceftazidime + cip-
rofloxacin. However, the wide confidence intervals are of 
attention and severity of sepsis based antimicrobial differ-
ences should be confirmed with further studies. Until more 
data emerges, sepsis severity should not be a parameter to 
influence empirical antimicrobial treatment decisions.
Appropriateness of using HAUTIs as representative 
of urosepsis
Evidence for urosepsis pathogen spectrum and resistance is 
gathered from complicated UTI reports [16, 17] and local 
surveillance data [6]. The current analysis identified that 
this approach is not appropriate as the pathogen spectrum 
and resistance are different in urosepsis compared to other 
HAUTIs. For instance, ceftazidime and levofloxacin, one 
of the recommended first-line treatments in urosepsis, [11] 
showed higher resistance in urosepsis than other HAUTIs 
(Table 2). Additionally, other antibiotics such as amoxicil-
lin + BLI, cefotaxime, cefuroxime, ceftazidime combined 
with ciprofloxacin or gentamicin and piperacillin/tazo-
bactam combined with ciprofloxacin had a significantly 
higher rate of resistance in urosepsis compared with other 
HAUTIs. In summary, the current analysis has shown that 
the pathogen spectrum and resistance rates in urosepsis are 
different than other HAUTIs.
Limitations of the current analysis
Lack of coordinated surveillance studies was pointed out 
by the World Health Organization as a major gap in the 
topic of global antimicrobial resistance [20]. Although the 
GPIU study is a coordinated global HAUTI surveillance 
study of urology patients, certain geographical areas are not 
well represented contributing to limitations of the current 
analysis. In particular, lack of larger data from Africa and 
USA makes it hard to draw conclusions for these regions.
The GPIU study is focused on urological hospitalised 
patients only. While this is a powerful domain, it may 
raise two issues: Firstly; it is highly likely that urosepsis 
patients managed in ICUs by other specialities have been 
missed. Therefore, we did not report on overall hospital 
prevalence and instead have reported prevalence in urol-
ogy departments. Secondly, participating centres may be 
more actively involved in infection control with a higher 
tendency of participating in surveillance studies. Therefore, 
the outcomes obtained should be approached cautiously 
and be regarded as indicators of the situation amongst 
urology practice. Moreover, these indicators should not be 
solely used as a recommendation for antibiotic treatment of 
HAUTIs, but as an indicator that needs to be tailored to the 
local situation.
Conclusion
It is not appropriate to use the pathogen spectrum and 
resistance of other clinical diagnosis of HAUTIs as repre-
sentative of urosepsis. In addition, the geographical vari-
ability of resistance rates makes it essential to have local 
surveillance reports on urosepsis separate from other HAU-
TIs in determining the appropriate empirical treatment. 
Adoption of the CDC/ECDC definitions of MDR for future 
epidemiological studies is necessary.
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